Merck


Breaking hostilities...to make a good move

09/04/19 -"Finally, Merck has successfully brought all parties to the negotiation table after having made a rival bid (see our Latest of 28/02/2019) to acquire Versum. But the ‘war’ is not over as ..."

Pages
56
Language
English
Published on
09/04/19
You may also be interested by these reports :
18/04/19
... than ‘freestyle’. Lonza announced its usual qualitative Q1 update. Besides the long description-filled pages of the updated business structure ...

18/04/19
Roche reports a strong start to the year and, consequently, upgrades the 2019 guidance. Q1 sales grew by 8% at CER with the growth coming ...

09/04/19
The Novartis share price readjusts lower following the demerger of Alcon, which was listed as a separate entity from 9 April 2019.

09/04/19
Finally, Merck has successfully brought all parties to the negotiation table after having made a rival bid (see our Latest of 28/02/2019) to acquire ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO